Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer

- Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer - TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D....

Full "IntellAsia: Resources" article